[pt. information/articles/articles-sidebar.htm] |
|
Preimplantation Genetic Diagnosis for Autosomal Recessive Polycystic
Kidney Disease
It now is possible for physicians to offer
preimplantation genetic diagnosis for autosomal recessive polycystic
kidney disease to couples at risk of bearing a child with this
disorder. The PGD procedure allows genetic testing to be performed
on early embryos before implantation for the purpose of selecting
only those embryos that are unaffected by ARPKD for uterine
transfer.
Children’s Hospital of Wisconsin, Froedtert Hospital and the Medical
College of Wisconsin offer PGD for ARPKD.
Couples who are known to be carriers and/or have had a child with
ARPKD and who are considering a pregnancy face a 1 in 4 (25 percent)
chance in each future pregnancy of having a child with the disease.
Some couples opt for prenatal diagnosis during pregnancy to
determine whether a pregnancy is affected.
An alternative to prenatal testing for ARPKD now is available using
in-vitro fertilization with PGD to identify an unaffected embryo.
In-vitro fertilization is the process of combining eggs and sperm to
form embryos in the laboratory. IVF is often used to help couples
with infertility have a child. Preimplantation genetic diagnosis is
a procedure to analyze the genetic make-up of embryos formed through
IVF for determination of disease status. Couples at risk for ARPKD
can use PGD to test for this disease. Based on this analysis,
embryos that are not affected with ARPKD can be selected for
transfer to the uterus to establish a pregnancy.
PGD process for the purpose of ARPKD testing
Parents and their affected child, if/when possible, will first
undergo blood tests to determine whether the PGD process will be
feasible. If these tests show that PGD is possible, the parents will
undergo an IVF cycle to form embryos.
The embryos created are sampled on the third day of development when
they have approximately 6 to 8 cells. One or two cells are taken
from each embryo for testing using PCR. The embryo is incubated
until testing is complete. Each embryo has a 1 in 4 chance of being
affected with ARPKD. By testing these cells for deletions in the
PKHD1 gene, only those embryos determined to be unaffected (having
one or two working copies of the gene) are selected for transfer
back into a woman’s uterus. Thus, the chance to have an unaffected
pregnancy is greatly increased.
The Risks of PGD
The biopsy technique required to perform PGD has been in use
since 1990. The likelihood of damage to an embryo during the removal
of cells is low, but it can occur. This can result in a decreased
chance of embryo survival. When compared to IVF without PGD, there
is a somewhat decreased chance for embryo survival among embryos
that have undergone PGD. IVF with PGD is not known to lead to an
increased chance for congenital abnormalities, birth defects, mental
retardation, or other abnormal development when compared to natural
pregnancies. However, a normal pregnancy outcome is not guaranteed.
Overall, PGD is an accurate process for determining whether an
embryo is affected with ARPKD. There is a small risk of error or
technical limitation that will prevent us from determining whether
the sampled embryos have ARPKD. Because of this and the fact that we
do not test for other genetic conditions or chromosome problems, the
option of testing early in pregnancy through prenatal diagnosis is
available.
Preventative Measure during PGD Cycle
It is important for couples undergoing PGD to alter their sexual
activity during the PGD cycle. Couples must refrain from intercourse
until the cycle is complete.
Cost of PGDM
IVF with PGD is expensive. Insurance companies generally do not
cover the cost of IVF with or without PGD. We will provide you with
a detailed cost analysis for IVF and PGD at your request.
Contact Information
Requests for information regarding the Children’s Hospital of
Wisconsin, Froedtert Hospital and Medical College of Wisconsin PGD
program and IVF can be obtained by contacting the Reproductive
Medicine Clinic at (414) 805-7370 or by sending e-mail to
pgd@mcw.edu. Information regarding PGD for the purpose of ARPKD
testing can be discussed in more detail with our geneticist or
genetic counselor. |